Trials / Completed
CompletedNCT00226707
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
A 6-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Pimecrolimus Cream 1% in Patients With Mild-to-Moderate Chronic Hand Dermatitis Followed by a 6-Week Open-Label Phase to Assess the Safety of Pimecrolimus Cream 1%
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 652 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimecrolimus Cream 1% |
Timeline
- Start date
- 2004-07-01
- Completion
- 2005-03-01
- First posted
- 2005-09-27
- Last updated
- 2008-02-15
Source: ClinicalTrials.gov record NCT00226707. Inclusion in this directory is not an endorsement.